Skip to main content
. 2024 Jul 30;14(8):5845–5860. doi: 10.21037/qims-24-729

Table 1. Clinical characteristics of patients on the training, internal test, external test, and prospective test sets.

Characteristics All sets (n=541) Training set (n=328) Internal test set (n=72) External test set (n=54) Prospective test set (n=87) P value
Age (years) 37.0±16.0 36.9±17.0 36.7±15.1 36.6±12.7 38.2±14.4 0.732
Sex 0.007
   Female 241 (44.5) 144 (44.0) 30 (41.7) 16 (29.6) 51 (58.6)
   Male 300 (55.5) 184 (56.0) 42 (58.3) 38 (70.4) 36 (41.4)
Disease duration# 12.0 (5.0, 48.0) 18.5 (6.0, 60.0) 12.0 (4.5, 60.0) 7.0 (1.5, 36.0) 12.0 (4.2, 48.0) 0.136
Structural damage 0.336
   Positive 303 (56.0) 177 (53.9) 39 (54.2) 36 (66.7) 51 (58.6)
   Negative 238 (44.0) 151 (46.1) 33 (45.8) 18 (33.3) 36 (41.4)
SpA features
   Arthritis 179 (33.1) 95 (28.9) 17 (23.6) 41 (75.9) 26 (29.9) <0.001
   Heel enthesitis 31 (5.7) 0 0 31 (57.4) 0 <0.001
   Uveitis 1 (0.1) 0 0 1 (1.9) 0 0.029
   Dactylitis 14 (2.6) 0 0 12 (22.2) 2 (2.3) <0.001
   Psoriasis 3 (0.6) 1 (0.3) 1 (1.4) 0 1 (1.1) 0.544
   Crohn’s disease or UC 4 (0.7) 2 (0.6) 0 1 (1.9) 1 (1.1) 0.632
   Good response to NSAIDs 334 (61.7) 234 (71.3) 58 (80.5) 14 (25.9) 28 (32.2) <0.001
   Family history of axSpA 58 (10.7) 27 (8.2) 18 (25.0) 8 (14.8) 5 (5.7) <0.001
   Elevated CRP concentration 181 (33.5) 114 (34.8) 22 (30.6) 32 (59.3) 13 (14.9) <0.001
Classification
   AxSpA 261 (48.2) 138 (42.1) 45 (62.5) 25 (46.3) 53 (60.9)
   Non-axSpA 280 (51.8) 190 (57.9) 27 (37.5) 29 (53.7) 34 (39.1)

Data are presented as median (Q1, Q3), mean ± standard deviation or number (%). P values represent the statistical differences among the training, internal, external, and prospective test sets. In the SpA features, data are numbers of positive patients with percentages in parentheses. M, months; UC, ulcerative colitis; NSAIDs, nonsteroidal anti-inflammatory drugs; axSpA, axial spondyloarthritis; CRP, C-reactive protein.